阿布昔替尼在中重度特应性皮炎治疗中的效果与安全性  

Effect and Safety of Abrocitinib in Treatment of Moderate to Severe Atopic Dermatitis

作　　者：周丹莹[1] 李亦聪[1] 叶辉胜[1] 冼信仁 ZHOU Danying;LI Yicong;YE Huisheng;XIAN Xinren(Guangzhou Xinhai Hospital,Guangzhou,Guangdong 510300)

机构地区：[1]广州新海医院,广东广州510300

出　　处：《智慧健康》2024年第35期49-51,55,共4页Smart Healthcare

摘　　要：目的探讨应用阿布昔替尼治疗中重度特应性皮炎(AD)的效果及安全性。方法回顾性分析2023年1月—2024年6月就诊于皮肤门诊科的53例中重度AD者,根据患者用药情况分成阿布昔替尼组(27例)、度普利尤单抗组(26例)。阿布昔替尼组应用阿布昔替尼治疗24周,度普利尤单抗组应用度普利尤单抗治疗24周。比较各组治疗前后不同时间点的湿疹面积及严重程度指数(EASI)评分、AD评分(SCORAD)评分,分析各组治疗前后嗜酸性粒细胞水平的变化,并记录治疗期间不良反应的发生情况。结果治疗后,两组患者EASI、SCORAD评分均低于治疗前,阿布昔替尼组治疗4周、12周、24周的EASI与SCORAD评分均低于度普利尤单抗组(P<0.05)。阿布昔替尼组药物达峰时间与稳态时间均短于度普利尤单抗组(P<0.05),阿布昔替尼组药物花费少于度普利尤单抗组(P<0.05)。治疗期间两组患者无明显不良反应。结论对中重度AD患者,采用阿布昔替尼治疗相较于度普利尤单抗治疗,能够有效改善湿疹和瘙痒症状,缩短药物达到峰值和稳态的时间,降低治疗成本,并且具有较高的治疗安全性,因此值得广泛推广。Objective To investigate the effect and safety of abrocitinib in treatment of moderate to severe atopic dermatitis(AD).Methods The paper reviewed and analyzed 53 patients with moderate to severe AD in dermatology department from January 2023 to June 2024,and divided them into two groups according to different treatment methods,27 cases in the abrocitinib group and 26 cases in the dupilumab group.The abrocitinib group was treated with abrocitinib for 24 weeks,while the dupilumab group with dupilumab for 24 weeks.Eczema area and severity index(EASI)scores and AD scores(SCORAD)at different times before and after treatment were compared,eosinophil levels before and after treatment were compared,incidence of adverse reactions during treatment was recorded statistically.Results After treatment,the EASI and SCORAD scores of two groups were lower than before.The EASI and SCORAD scores of the abrocitinib group were lower than the dupilumab group at 4,12 and 24 weeks of treatment(P<0.05).The peak time and steady-state time of the abrocitinib group was shorter than the dupilumab group(P<0.05),drug cost of the abrocitinib group was lower than the dupilumab group(P<0.05).During treatment period,there were no significant adverse reactions in two groups.Conclusion Abrocitinib can improve eczema and itching symptoms,shorten drug peak time and steady state time,reduce treatment costs of patients with moderate to severe AR,with higher safety than dupilumab,which is worthy of promotion.

关 键 词：中重度特应性皮炎 阿布昔替尼 度普利尤单抗 嗜酸性粒细胞 不良反应 

分 类 号：R75[医药卫生—皮肤病学与性病学]